Celanese Discusses Innovative Uses for EVA Polymers at AAPS
Thu, October 30 2014
EVA applications expanded into oral dosage
At the AAPS annual meeting and expo, Celanese will meet with leaders in the pharmaceutical and medical industries to discuss potential uses of EVA in two ways: as controlled release of drugs for oral administration, and EVA as a foamed excipient to deliver stem cells, growth factors and biologics.
“EVA polymers have a successful history in the pharmaceutical industry
as a parenteral controlled release excipient,” said
EVA in oral applications
The Celanese whitepaper entitled Potential Use of Ethylene Vinyl Acetate Copolymer Excipients in Oral Controlled Release Applications: A Literature Review summarizes the recent developments of EVA-based oral controlled release drug delivery systems. Fifty separate references are cited in this comprehensive paper.
EVA as a foamed excipient
In the Celanese whitepaper entitled EVA Foamed Excipient:
Technical, marketing and sales teams will be available at the Celanese
booth #1150 at the AAPS expo to discuss the various uses of EVA polymers
for controlled release. To set up a meeting at the expo, please contact
About Celanese
All trademarks indicated above are owned by
Forward-Looking Statements
This release may contain “forward-looking statements,” which include
information concerning the company's plans, products, objectives, goals,
strategies, future revenues or performance, capital expenditures, and
other information that is not historical information. When used in this
release, the words “expects,” “anticipates,” “projects,” “plans,”
“intends,” “believes,” “may,” “can,” “could,” “would,” “might,” “will”
and variations of such words or similar expressions are intended to
identify forward-looking statements. All forward-looking statements are
based upon current expectations and beliefs and various assumptions.
There can be no assurance that the company or its customers will realize
these benefits or that these beliefs will prove correct. There are a
number of risks and uncertainties that could cause actual results to
differ materially from the results expressed or implied in the
forward-looking statements contained in this release. These risks and
uncertainties include, among other things: changes in general economic,
business, political and regulatory conditions; changes in the price and
availability of raw materials; the introduction of competing products by
other companies; market acceptance of our products; changes in the
degree of intellectual property and other legal protection afforded to
our products and processes; the impact of technological developments and
competition; adoption of new or different industry or regulatory
standards; unanticipated operational or commercial difficulties,
including failure of facilities or processes or products to be designed
or constructed, or to operate, in accordance with specifications or
expectations; the ability to achieve and maintain plant
utilization; ability of third parties, including our commercial
partners, suppliers or others, to comply with their commitments to us;
increased costs under existing or future environmental regulations,
including those relating to climate change; potential liability
resulting from pending or future litigation, or from changes in the
laws, regulations or policies of governments or other governmental
activities in the countries in which we operate; and various other
factors discussed from time to time in the company's filings with the
Investor Relations
Jon.Puckett@celanese.com
or
Media
- Corporate
William.Jacobsen@celanese.com
Source: